Mitochondrial dynamics and mitophagy in the 6-hydroxydopamine preclinical model of Parkinson's disease [0.03%]
6-羟多巴胺帕金森病前临床模型中的线粒体动力学和线粒体自噬作用
Maria F Galindo,Maria E Solesio,Sandra Atienzar-Aroca et al.
Maria F Galindo et al.
We discuss the participation of mitochondrial dynamics and autophagy in the 6-hydroxidopamine-induced Parkinson's disease model. The regulation of dynamic mitochondrial processes such as fusion, fission, and mitophagy has been shown to be a...
The Protective Effect of Minocycline in a Paraquat-Induced Parkinson's Disease Model in Drosophila is Modified in Altered Genetic Backgrounds [0.03%]
遗传背景改变对甲硝唑改善果蝇百草枯诱导的帕金森病的影响
Arati A Inamdar,Anathbandhu Chaudhuri,Janis O&#x;Donnell
Arati A Inamdar
Epidemiological studies link the herbicide paraquat to increased incidence of Parkinson's disease (PD). We previously reported that Drosophila exposed to paraquat recapitulate PD symptoms, including region-specific degeneration of dopaminer...
A novel, sensitive assay for behavioral defects in Parkinson's disease model Drosophila [0.03%]
一种新颖的帕金森病模式果蝇行为缺陷敏感测定法
Ronit Shaltiel-Karyo,Dan Davidi,Yotam Menuchin et al.
Ronit Shaltiel-Karyo et al.
Parkinson's disease is a common neurodegenerative disorder with the pathology of α-synuclein aggregation in Lewy bodies. Currently, there is no available therapy that arrests the progression of the disease. Therefore, the need of animal mo...
L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain [0.03%]
多巴胺前体物质左旋多巴在大鼠脑血管周围足板细胞中的聚集现象研究进展
M Y Inyushin,A Huertas,Y V Kucheryavykh et al.
M Y Inyushin et al.
Astrocyte endfeet surround brain blood vessels and can play a role in the delivery of therapeutic drugs for Parkinson's disease. However, there is no previous evidence of the presence of LAT transporter for L-DOPA in brain astrocytes except...
Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects [0.03%]
2012年帕金森病非运动症状的临床相关方面
Anne Marie Bonnet,Marie France Jutras,Virginie Czernecki et al.
Anne Marie Bonnet et al.
Nonmotor symptoms (NMSs) of Parkinson's disease (PD) are common, but they are often underrecognized in clinical practice, because of the lack of spontaneous complaints by the patients, and partly because of the absence of systematic questio...
Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease [0.03%]
多巴胺能药物和移植诱导的异动症动物模型中的血清素神经元的作用研究
Eunju Shin,Elisabetta Tronci,Manolo Carta
Eunju Shin
L-DOPA, the most effective drug to treat motor symptoms of Parkinson's disease, causes abnormal involuntary movements, limiting its use in advanced stages of the disease. An increasing body of evidence points to the serotonin system as a ke...
Micaela Morelli,Fabio Blandini,Nicola Simola et al.
Micaela Morelli et al.
Dyskinesia, a major complication of treatment of Parkinson's disease (PD), involves two phases: induction, which is responsible for dyskinesia onset, and expression, which underlies its clinical manifestation. The unique cellular and region...
αSynuclein and Mitochondrial Dysfunction: A Pathogenic Partnership in Parkinson's Disease? [0.03%]
α-突触核蛋白与线粒体功能障碍：帕金森病中的致病性伙伴关系？
David Protter,Charmaine Lang,Antony A Cooper
David Protter
Parkinson's Disease (PD) is a complex, chronic, progressive, and debilitating neurodegenerative disorder. Neither a cure nor effective long-term therapy exist and the lack of knowledge of the molecular mechanisms responsible for PD developm...
An NR2B-Dependent Decrease in the Expression of trkB Receptors Precedes the Disappearance of Dopaminergic Cells in Substantia Nigra in a Rat Model of Presymptomatic Parkinson's Disease [0.03%]
在帕金森病前期模型大鼠黑质多巴胺能神经元缺失前trkB受体NR2B依赖性表达降低
Eduardo Riquelme,Jorge Abarca,Jorge M Campusano et al.
Eduardo Riquelme et al.
Compensatory changes occurring during presymptomatic stages of Parkinson's disease (PD) would explain that the clinical symptoms of the disease appear late, when the degenerative process is quite advanced. Several data support the propositi...
Intensive rehabilitation treatment in parkinsonian patients with dyskinesias: a preliminary study with 6-month followup [0.03%]
伴有肌张力障碍的帕金森病患者强化康复治疗初步研究（6个月随访）
Giuseppe Frazzitta,Micaela Morelli,Gabriella Bertotti et al.
Giuseppe Frazzitta et al.
A major adverse effect of levodopa therapy is the development of dyskinesia, which affects 30-40% of chronically treated Parkinsonian patients. We hypothesized that our rehabilitation protocol might allow a reduction in levodopa dosage with...